Akums launches Doxylamine + Pyridoxine ER tablets

Akums Drugs and Pharmaceuticals announced the launch of Doxylamine + Pyridoxine extended-release tablets, a therapy approved by the CSDCO, India and the USFDA.

Doxylamine, a competitive histamine H1 receptor inhibitor with sedative and anticholinergic effects, is paired with Pyridoxine Hydrochloride (Vitamin B6), known for its anti-emetic properties and its role in haemoglobin production and neurotransmitter metabolism. This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy.

A statement from the company informed that Akums’ Doxylamine 20 mg + Pyridoxine 20mg extended-release tablet incorporates an immediate-release layer, allowing for a swift onset of action following ingestion. Simultaneously, the extended-release feature ensures prolonged and consistent relief from symptoms offering an effective and comprehensive solution for managing nausea and vomiting in pregnancy.